181 related articles for article (PubMed ID: 20143319)
1. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer.
Urayama S; Zou W; Brooks K; Tolstikov V
Rapid Commun Mass Spectrom; 2010 Mar; 24(5):613-20. PubMed ID: 20143319
[TBL] [Abstract][Full Text] [Related]
2. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
5. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
7. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
8. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
9. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Alnatsha A; Li Q; Oehrle B; Weiss FU; Sendler M; Distler M; Uhl W; Fahlbusch T; Goni E; Beyer G; Chromik A; Bahra M; Klein F; Pilarsky C; Grützmann R; Lerch MM; Lauber K; Christiansen N; Kamlage B; Regel I; Mayerle J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359990
[TBL] [Abstract][Full Text] [Related]
10. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
[TBL] [Abstract][Full Text] [Related]
11. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
12. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma.
Moore HB; Culp-Hill R; Reisz JA; Lawson PJ; Sauaia A; Schulick RD; Del Chiaro M; Nydam TL; Moore EE; Hansen KC; D'Alessandro A
Am J Surg; 2019 Dec; 218(6):1206-1212. PubMed ID: 31514959
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of pancreatic cancer via
Michálková L; Horník Š; Sýkora J; Habartová L; Setnička V
Analyst; 2018 Dec; 143(24):5974-5978. PubMed ID: 30270368
[TBL] [Abstract][Full Text] [Related]
14. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
15. Protein-metabolite panel for early-stage pancreatic cancer.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
[No Abstract] [Full Text] [Related]
16. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
18. Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors.
Liu Z; Yin P; Amathieu R; Savarin P; Xu G
Anal Bioanal Chem; 2016 Nov; 408(27):7641-7649. PubMed ID: 27614981
[TBL] [Abstract][Full Text] [Related]
19. [Gastroenterological Cancer Diagnosis by Metabolomics-Discovery of Pancreatic Cancer Biomarker].
Yoshida M; Nishiumi S; Azuma T
Rinsho Byori; 2015 Apr; 63(4):450-6. PubMed ID: 26536778
[TBL] [Abstract][Full Text] [Related]
20. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
